<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Germanos M</submitter><funding>State Government of Victoria</funding><funding>NHMRC</funding><funding>National Institutes of Health</funding><funding>University of Sydney</funding><funding>NIGMS NIH HHS</funding><pagination>111719</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11787600</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>28(2)</volume><pubmed_abstract>In type 2 diabetes (T2D), the rate of insulin secretory granule biogenesis can limit insulin secretion from pancreatic β-cells. Using rat insulinoma INS1 β-cells, we show that the soluble Ca&lt;sup>2+&lt;/sup>-binding/trafficking protein, Cab45G, serves as a non-essential chaperone for insulin granule biogenesis. In β-cells, Cab45G is stored within a &lt;i>cis&lt;/i>-Golgi reservoir. Cab45G deletion dysregulates Ca&lt;sup>2+&lt;/sup> homeostasis and leads to secretory abnormality, but insulin granule biogenesis remains intact. Increasing Cab45G biosynthesis leads to anterograde trafficking into insulin granules, stimulating their production. Using human donor islets, we identify increased anterograde Cab45G trafficking in obese humans with and without T2D, consistent with the heightened demand for granule b</pubmed_abstract><journal>iScience</journal><pubmed_title>Cab45G trafficking through the insulin secretory pathway is altered in human type 2 diabetes.</pubmed_title><pmcid>PMC11787600</pmcid><funding_grant_id>GNT1139828</funding_grant_id><funding_grant_id>R35 GM149293</funding_grant_id><funding_grant_id>R01 GM121481</funding_grant_id><pubmed_authors>Needham EJ</pubmed_authors><pubmed_authors>Germanos M</pubmed_authors><pubmed_authors>Naghiloo S</pubmed_authors><pubmed_authors>Masler D</pubmed_authors><pubmed_authors>Thomas H</pubmed_authors><pubmed_authors>Yeoman C</pubmed_authors><pubmed_authors>Ailion M</pubmed_authors><pubmed_authors>Wilson A</pubmed_authors><pubmed_authors>Diaz-Vegas A</pubmed_authors><pubmed_authors>Thorn P</pubmed_authors><pubmed_authors>Larance M</pubmed_authors><pubmed_authors>Taper M</pubmed_authors><pubmed_authors>Asensio C</pubmed_authors><pubmed_authors>van der Kraan AG</pubmed_authors><pubmed_authors>Tong J</pubmed_authors><pubmed_authors>von Blume J</pubmed_authors><pubmed_authors>Kebede MA</pubmed_authors><pubmed_authors>An Y</pubmed_authors><pubmed_authors>Loudovaris T</pubmed_authors><pubmed_authors>Yau B</pubmed_authors><pubmed_authors>Cattin-Ortola J</pubmed_authors><pubmed_authors>Sun K</pubmed_authors></additional><is_claimable>false</is_claimable><name>Cab45G trafficking through the insulin secretory pathway is altered in human type 2 diabetes.</name><description>In type 2 diabetes (T2D), the rate of insulin secretory granule biogenesis can limit insulin secretion from pancreatic β-cells. Using rat insulinoma INS1 β-cells, we show that the soluble Ca&lt;sup>2+&lt;/sup>-binding/trafficking protein, Cab45G, serves as a non-essential chaperone for insulin granule biogenesis. In β-cells, Cab45G is stored within a &lt;i>cis&lt;/i>-Golgi reservoir. Cab45G deletion dysregulates Ca&lt;sup>2+&lt;/sup> homeostasis and leads to secretory abnormality, but insulin granule biogenesis remains intact. Increasing Cab45G biosynthesis leads to anterograde trafficking into insulin granules, stimulating their production. Using human donor islets, we identify increased anterograde Cab45G trafficking in obese humans with and without T2D, consistent with the heightened demand for granule b</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Feb</publication><modification>2026-06-01T10:27:36.091Z</modification><creation>2025-04-19T16:25:28.297Z</creation></dates><accession>S-EPMC11787600</accession><cross_references><pubmed>39898024</pubmed><doi>10.1016/j.isci.2024.111719</doi></cross_references></HashMap>